BBM Performance Standards
The Global CEO Initiative on Alzheimer’s Disease performance recommendations for blood-based biomarker tests
Published in Nature Reviews Neurology
Blood tests for Alzheimer's could revolutionize Alzheimer's diagnosis since they are more affordable and accessible compared to existing tools. But without clear standards, understanding how and where to use BBMs was a major barrier.
To address this challenge, CEOi convened stakeholders from healthcare, academia, non-profit, government, industry, and patient advocacy to prepare for the widespread adoption of BBMs in clinical practice -- enabling a more simple, timely, and accurate diagnostic experience for patients.
To address this challenge, CEOi convened stakeholders from healthcare, academia, non-profit, government, industry, and patient advocacy to prepare for the widespread adoption of BBMs in clinical practice -- enabling a more simple, timely, and accurate diagnostic experience for patients.
CEOi Performance Standards for Blood-based Biomarkers
Key Takeaways from the Publication
- BBM tests can be used to confirm disease pathology without further PET or CSF testing, or use as a triaging tool with subsequent confirmatory testing.
- When used as a confirmatory tool, performance standards should be equivalent to cerebrospinal fluid (CSF) tests, which is 90% sensitivity and specificity.
- When used in triaging, at least 90% sensitivity, and at least 85% specificity in primary care or 75% in secondary care settings.
See How the Performance of Available Blood Tests Compares to CEOi’s Standards
As innovation with blood tests for Alzheimer’s disease accelerates, understanding how each test performs against the CEOi performance standards helps in making evidence-based decisions for patient care.
Our Blood Test Performance Database provides information on a variety of tests in one, easy to use resource.
Access the Blood Test Performance DatabaseOur Blood Test Performance Database provides information on a variety of tests in one, easy to use resource.
Discover the Impact of BBMs on Alzheimer’s Diagnoses from Workgroup Co-Lead Suzanne Schindler
Educational Resources For
Blood-Based Biomarkers
View Additional BBM Resources Here
Press & Media
Thank you to everyone who contributed to this effort:
- Suzanne Schindler, Washington University School of Medicine
- Oskar Hansson, Lund University; Memory Clinic, Skane University Hospital
- Douglas Galasko. University of California, San Diego
- Ana Pereira, Icahn School of Medicine, Mount Sinai
- Gil Rabinovici, University of California, San Francisco
- Stephen Salloway, Brown University
- Marc Suarez-Calvet, Barcelonaβeta Brain Research Center
- Ara Khachaturian, The Campaign to Prevent Alzheimer’s Disease
- Michelle Mielke, Wake Forest University School of Medicine
- Chi Udeh-Momoh, Wake Forest University School of Medicine
- Joan Weiss, Health Resources and Services Administration
- Richard Batrla, Eisai
- Sasha Bozeat, F. Hoffman–La Roche AG
- John Dwyer, Global Alzheimer’s Platform Foundation
- Drew Holzapfel, The Global CEO Initiative on Alzheimer’s Disease
- Daryl Rhys Jones, Eisai
- James Murray, Davos Alzheimer’s Collaborative
- Katherine Partrick, The Global CEO Initiative on Alzheimer’s Disease
- Emily Scholler, The Global CEO Initiative on Alzheimer’s Disease
- George Vradenburg, Davos Alzheimer’s Collaborative;UsAgainstAlzheimer’s
- Dylan Young, Guidehouse
- Alicia Algeciras-Schimnich, Mayo Clinic, Rochester
- Jiri Aubrecht, Prothena Biosciences
- Joel Braunstein, C2N Diagnostics
- James Hendrix, Eli Lilly and Company
- Yan Helen Hu, Eisai
- Soeren Mattke, University of Southern California
- Mark Monane, C2N Diagnostics
- David Reilly, Guidehouse
- Elizabeth Somers, Eisai Inc
- Charlotte E. Teunissen, Amsterdam University Medical Centers
- Eli Shobin, Biogen
- Hugo Vanderstichele, Biomarkable BV
- Michael Weiner University of California
- David Wilson, Quanterix Corporation